Article Text

other Versions

Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations

Statistics from

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview

Review history and Supplementary material

  • Competing interests: AL has received fees for speaking, research or travel support from AstraZeneca, Merck Sharp & Dhome, Pfizer, Almirall Prodesfarma and TAP. LAG-R has received fees for speaking from Merck Sharp & Dhome, Pfizer and AstraZeneca, and research grants from Pfizer and AstraZeneca. FG, EQ, LR and JMP have received fees for speaking and research grants or travel support from AstraZeneca, Merck, Pfizer and Almirall Prodesfarma. The other authors have not reported conflict of interest.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.